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Introduction 
Dyspepsia is a very common set of clinical symptoms. 
Clear-cut scientific evidence of the effectiveness of diag­
nostic schemes is unavailable for most clinical situations 
related to dyspepsia. For this and other reasons, practice 
patterns vary widely. The development of explicit detailed 
criteria of appropriateness of use of endoscopy is an at­
tempt to produce best available evidence (based on a vali­
dated panel process and expert j udgmen t ) where better evi­
dence is lacking, with the aim to assist the clinician in dai­
ly decision making. 
In November 1998, a mult idiscipl inary European expert 
panel convened in Lausanne, Switzerland, to discuss and 
develop criteria for the appropriate use of gastrointestinal 
endoscopy, a widely-used procedure, regarded as highly ac­
curate and safe. The R A N D appropriateness method was 
chosen for this purpose, because it a l lows the development 
of appropriateness criteria based on published evidence and 
supplemented by explicit expert opinion. A detailed de­
scription of the R A N D appropriateness method, including 
the literature search process [1], and of the whole process, 
as well as the global results of the panel [2], are published 
as separate articles in this issue of the Journal . The litera­
ture review was based on a systematic search of Medl ine , 
Embase and the Cochrane Library conducted up to the end 
of 1997 and completed with some key articles published in 
1998. Updating and revision of the literature review is cur­
rently ongoing. 
This article presents a literature review on dyspepsia , that 
was provided to the panelists to study and comment prior 
to the panel meet ing to support their ratings of appropriate­
ness of use of upper gastrointestinal endoscopy. This article 
furthermore presents an overview of the main panel results 
related to dyspepsia and a summary of published evidence 
and panel-based appropriateness criteria. 
1 . Literature Review 
Definition of Dyspepsia 
Evaluation of dyspepsia is reportedly the most frequent in­
dication for upper endoscopy referrals [3]. Al though com­
monly used by cl inicians, the term dyspepsia has not been 
uniformly defined, thus compl ica t ing the critical review of 
the literature relating dyspepsia to patient ou tcome. To per­
mit standardisation of te rminology and a better understand­
ing of dyspepsia, a 1988 working group [4] established the 
following classification: Dyspepsia is either organic (that 
is, due to specific lesions such as peptic ulcer, esophagit is , 
gastric carc inoma or other pathologies) or non-organic (up­
per abdominal discomfort for which no focal lesion is 
responsible) . Four dyspepsia sub-groups were defined, 
based on predominant symptoms and potential etiologies 
[4 ,5 ] : ulcer-l ike, reflux-like, dysmoti l i ty- l ike, non-specif ic . 
An international working par ty consensus [6] defined dys­
pepsia as episodic or persistent abdominal symptoms , often 
related to food intake, which patients or physicians believe 
to be due to disorders of the proximal port ion of the diges­
tive tract. At the Maastr icht consensus conference in 1997, 
a workshop on dyspepsia [7] adopted the following defini­
tion of dyspepsia: pain or discomfort in the upper abdo­
men, including nausea, vomit ing, early satiety, epigastric 
fullness and regurgitation but not heartburn or dysphagia. 
The development of a reliable tool providing a global 
measurement scale for severity of dyspepsia is a difficult 
task, due to the difficulty in defining dyspepsia uniformly. 
The Glasgow dyspepsia severity score, a global measure­
ment scale for dyspepsia , seems to be a valid, reproducible 
tool but no definition of dyspepsia is given and no distinc­
t ion is m a d e between the different forms of dyspepsia [8]. 
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Table 1 Prevalence of endoscopic changes in dyspeptic patients 
Heikkinen 1995 Sobala 1991 Patel 1994 Vaira 1 997 Vaira 1997 Mansi 1993 
n (%) n (%) n (%) n (%) n (%) n (%) 
Normal 254 (63) 169 (58) 75 (63) 807 (25) 359 (23) 630 (28) 
Gastritis/erosions 0 (0 ) 16(5 ) 0 (0 ) 1214 (38) 757 (47) 783 (35) 
Duodenitis 9 (2 ) 17(6 ) 12 (10) 430 (1 3) 214 (13) 328 (14) 
Gastric ulcer 17 (4) 17 (6) 4 ( 3 ) 1 1 9 (4) 55 (3) 35 (2) 
Duodenal ulcer 34 (9) 25 (8 ) 15 (13) 474 (1 5) 1 55 (10) 1 10 (5) 
Gastric cancer/malignancy 9 (2) 5 (2 ) 1 (D 24 (1 ) 12 (1) 45 (2) 
Esophagitis 59 (1 5) 44 (1 5) 12 (10) NA NA 295 (13) 
Other diagnoses 18 (5) 0 (0 ) 0 (0 ) 1 1 9 (4) 49 (3) 27 (1) 
Total 400 293 / 79 3187 7607 2253 
NA: not assessed. 
A severity quest ionnaire of the eight most frequently oc­
curr ing and most severe symptoms of dyspepsia has recent­
ly been validated for research purposes [9]. 
Symptom pattern has a poor predict ive value for the under­
lying cause of dyspepsia (see sub-chapter 1.4), and we 
have thus elected to group patients with upper abdominal 
symptoms as defined above, using the term "dyspeps ia" 
in the indication matr ix . This summary specifically refers 
to uncompl ica ted dyspept ic symptoms and the average-risk 
patient. Patients wi th weight loss, anemia, evidence of gas­
trointestinal bleeding, obstruct ion, dysphagia or odynopha­
gia, immunodef ic iency or other systemic illnesses are not 
considered to be typical patients in the context of the sum­
mary which follows. Fur thermore , patients present ing with 
isolated hear tburn or regurgitat ion are discussed in a sepa­
rate article on G E R D in this issue of the Journal [10] . 
Occurrence of Dyspepsia 
The prevalence of dyspeptic symptoms in the general pop­
ulation is es t imated to be 14 to 41 % [7 ,11 - 1 3 ] , with geo­
graphical differences in the prevalence of dyspepsia , for 
example between Sweden ( 1 9 % ) and England ( 4 1 % ) [14]. 
Populat ion surveys suggest that about 25 % of patients with 
dyspepsia seek medical at tention [12 ,15] . The prevalence 
of dyspepsia is characterised by an important turnover 
when measur ing onset and disappearance rates [11]. John-
sen et al. examined the associat ion between dyspeptic 
symptoms and endoscopic and histological d iagnoses . With 
the except ions of peptic ulcer disease and endoscopic duo­
denitis, they found no associat ion of clinical value [16]. 
Etiology of Dyspepsia 
A m o n g random dyspeptic patients , endoscopy is consid­
ered normal in 25 to 7 6 % [ 1 7 - 2 5 ] . Table 1 shows the 
prevalence of endoscopic changes in dyspept ic patients 
(combined results of five European prospect ive studies in­
cluding 7,853 pat ients) . 
Many gastroenterologists and pathologists have come to 
realise that endoscopic appearances frequently do not pre­
dict histological alterations. Gastric biopsy is therefore an 
essential part of routine endoscopic examination regardless 
of the macroscopic appearance of the mucosa [26]. 
Increasing age is related to higher frequency of organic 
disease in dyspeptic patients [ 1 7 , 2 0 , 2 1 , 2 7 - 3 0 ] , Cancer is 
rarely found in patients below 45 years of age. Table 2 il­
lustrates the aggregate results of three studies [17 ,20 .21] . 
Hel icobacter status has a significant influence on the prev­
alence of organic disease at endoscopy in patients with 
dyspepsia. Most gastric and duodenal ulcers, and most gas­
tric cancers are thus associated with a positive Helicobac­
ter status; erosive and non-erosive gastritis as well as duo­
denitis are significantly more frequent in Helicobacter-po-
sitive than in Helicobacter-negat ive patients, whereas the 
frequency of esophagit is does not seem to be different be­
tween the two groups. Table 3 shows the prevalence of or­
ganic disease in dyspeptic patients with respect to HP sta­
tus (combined results [ 1 7 - 1 9 ] , including a total of 1.964 
patients). 
Predictive Value of Symptoms for Organic Diagnosis 
in Dyspepsia 
The classification of ulcer-like, reflux-like, dysmotilitv-
like, non-specif ic symptoms was first formally tested b \ 
Talley [23]. In a prospect ive evaluation of 820 outpatients 
referred for endoscopy, 31 % of patients fitted into more 
than one historical dyspepsia subgroup, and 27 had non­
specific symptoms that could not be classified. Symptom?, 
alone were not found to be sensitive in differentiating pa­
tients with organic disease from patients with non-organic 
symptoms . These findings were confi rmed in other studies 
[ 2 1 , 3 1 - 3 3 ] . Dysmoti l i ty- l ike dyspepsia was found to re­
sult more often in a negative endoscopy [21]. There was 
no predict ive value as regards the patients ' predictions of 
their own diagnoses [32]. In a simulation study of three 
dyspeptic symptom complexes performed with general 
pract i t ioners, it was recently found that there is a consider-
D
ow
nl
oa
de
d 
by
: B
ib
lio
th
èq
ue
 C
an
to
na
le
 e
t U
ni
ve
rs
ita
ire
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
1. Appropriateness of Gastroscopy: Dyspepsia Endoscopy 1999; 31 581 
Table 2 Prevalence of endoscopic changes in dyspeptic patients, by age category 
Heikkinen 1995 
< 45 % > 4 5 % 
Mansi 
< 4 0 
1993 
% > 4 0 % 
Vaira 
< 4 5 
1997 
% > 4 5 % 
Normal 66 73 188 61 1 52 37 478 26 613 29 553 21 
Gastritis/erosions 0 0 0 0 80 19 703 38 788 38 1 183 44 
Duodenitis 1 1 8 3 75 18 253 14 290 14 354 1 3 
Gastric ulcer 1 1 16 5 1 1 3 24 1 45 2 129 5 
Duodenal ulcer 3 3 31 10 51 12 59 3 280 13 349 13 
Gastric cancer/ 0 0 9 3 0 0 45 2 2 0 34 1 
malignancy 
Other diagnoses 20 22 57 18 42 10 280 15 78 4 90 3 
Total 97 7 00 309 700 47 7 7 00 1842 7 00 2096 100 2692 7 00 
Table 3 Prevalence of organic disease in dyspeptic patients wi th respect to HP status [ 1 7 - 1 9 ] 
Total HP pos % pos Total HP neg % neg Total % 
Normal 279 22 324 47 603 31 
Gastritis/erosions 522 41 251 36 773 39 
Oesophagitis 27 2 29 4 56 3 
Duodenitis 179 14 64 9 243 12 
Gastric ulcer 58 5 18 3 76 4 
Duodenal ulcer 187 15 8 1 195 10 
Gastric cancer/malignancy 16 1 2 0 18 1 
Total 7268 7 00 696 7 00 7 964 7 00 
able variation in the reliability with which different symp­
toms are reported [34], which may partially explain the in­
ability of conventional history-taking to identify the cause 
of dyspepsia. 
Appropriate prel iminary screening of patients with acute 
dyspepsia can separate a group at low risk w h o will require 
investigations only if their symptoms do not resolve from a 
group at high risk requiring urgent outpatient consultat ions 
[35]. Numans et al. found that pain on an empty s tomach, 
absence of pain after a meal , together with age, sex, infor­
mation on former dyspeptic diseases, medicat ion and 
smoking could predict peptic ulcer with an A U C (area un­
der the curve) of 0.78 [36]. In the study of Muris et al. 
higher age, male sex, pain at night, relief by antacids or 
food and previous history of peptic ulcer disease were 
identified as predictors of organic cause for abdominal 
symptoms [37]. 
Helicobacter pylori in Dyspepsia 
Prevalence/Incidence of Helicobacter pylori 
Helicobacter pylori is found in 10 to 5 2 % of asymptomat ic 
individuals [ 8 , 3 8 - 4 2 ] . The prevalence of H P increases 
with age but is not correlated with gender [ 3 9 - 4 1 ] . With 
the advent of improved living condit ions, the incidence of 
HP infection has probably decreased over the generat ions 
[43,44] . 
Relat ionship between Hel icobacter pylori and 
Peptic Ulcer Disease (PUD) 
Various investigators have documented H. pylori infection 
in 90 to 1 0 0 % of patients with duodenal ulcers and 70 to 
9 0 % of patients with gastric ulcers [ 4 5 - 4 7 ] . In patients 
with duodenal ulcers, Hel icobacter eradication results in 
long-lasting remission. At one year, ulcers had recurred in 
2 % of antibiotic-treated patients compared to 85 % of un­
treated patients [48]. H. pylori t rea tment has also been 
shown to be effective in prevent ing recurrence of gastric 
ulcers. One study documented a 2-year recurrence rate of 
1 3 % in patients with gastric ulcers randomised to treat­
ment with triple antibiotic therapy, compared to 7 4 % of 
the group treated with ranitidine only [45]. 
Relat ionship between Hel icobacter pylori 
and Non-Ulcer Dyspepsia ( N U D ) 
In contrast to gastroduodenal ulcer disease, gastric malig­
nancy and proven gastritis, there is still a lack of convin­
cing evidence of a causal relat ionship between Hel icobac­
ter pylori and N U D [7 ,49] . Most studies thus did not re­
port a significant difference in symptoms between Helico-
bacter-posit ive and Hel icobacter-negat ive patients with 
non-ulcer dyspepsia [ 5 0 - 5 2 ] . A recent French consensus 
conference summar ised the results of 15 studies which at­
tempted to establish a causal link between HP infection 
and dyspepsia [53]: the level of evidence for such an asso-
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ciation is poor. A recent meta-analysis of H P prevalence 
rates in N U D and asymptomat ic control patients indicates 
that prevalence is greater in patients with N U D than in 
the controls (difference 2 3 % ) [54] . The studies analysed 
were, however, he terogeneous and the definition of dyspep­
sia was not standardised, mak ing compar isons difficult. 
Studies evaluating the impact of eradication t reatment in 
N U D have not yielded convincing results. Almost all stud­
ies showed major methodological flaws, including small 
sample size, lack of long-term follow-up and use of ill-de­
fined ou tcome measures . Some of these studies have 
shown improvement of symptoms after eradication [ 5 5 -
59] while others failed to show any such improvement 
[ 5 0 , 6 0 - 6 2 ] . In 1998, four placebo-control led randomised 
trials were reported in abstract form of which one showed 
improvement of symptoms after eradication t reatment [63] , 
whereas the three others did not [ 6 4 - 6 6 ] . In the posit ive 
English M R C trial [63], 2 1 % of the patients that had re­
ceived eradicat ion t reatment were asymptomat ic after one 
year, compared to 7 % w h o received placebo t reatment . Al ­
though this is statistically significant, the therapeutic gain 
was only 1 4 % , and the 7 % placebo rate found in this study 
is surprisingly low. If we compare these results wi th the 
Austral ian study [66], we see that the p lacebo response 
rates after one year were similar, 2 1 . 8 % versus 2 4 . 1 % , 
after eradication treatment . 
It has to be r emembered that the Maastr icht r ecommenda­
tions support ing eradication t reatment in non-ulcer dyspep­
sia [7] contradict the N I H consensus [67] and the recom­
mendat ions of the British Society of Gastroenterology [68] . 
A systematic review of various drug t reatments in function­
al dyspepsia , summar is ing data for 3,978 patients from 52 
trials, did not provide evidence of an effective t reatment 
for N U D [69]. 
Diagnosis of Hel icobacter pylori Infection 
Diagnosis of Hel icobacter pylori infection can be made by 
invasive tests, requir ing endoscopy (histology, cultures, 
PCR, rapid urease test) or non-invasive tests ( l 3 C - u r e a 
breath-test , serology). These tests vary in sensitivity and 
specificity but mos t of them are highly accurate [70] (Ta­
ble 4) . 
The gold-s tandard for diagnosis of H P infection is endo­
scopic biopsy of the antral mucosa with histological confir­
mat ion of the organism's presence [71]. The CLO-tes t is 
the most widely used and studied rapid urease test with 
m a x i m u m sensitivity 24 hours after biopsy [72]. Serology 
is r ecommended for non-endoscopic screening. C o m m e r ­
cially available serological kits for H P infection show an 
overall sensitivity of 8 5 % and a specificity of 7 9 % , wi th 
no test being found to be more accurate than any other 
[73]. The performance of pract ice-based serological kits 
may need to be improved before r ecommend ing their gen­
eral use for screening. The urea breath-test is the best non-
Table 4 Sensitivity of diagnostic tests for Helicobacter pylori (Me-
graud [70]) 
Sensitivity % Specificity % 
Histology 93.6 97.7 
Culture 98.4 100 
PCR 96.7 100 
Rapid urease test 90.2 100 
1 3 C-urea breath test 100 100 
Serology 98.4 88.4 
invasive test to determine eradication [74]. The major dis­
advantage of non-invasive tests compared to endoscopy is 
their lack of anatomical information about the presence of 
gastroduodenal ulceration. 
Efficacy of Eradication Treatment 
Eradicat ion of Hel icobacter pylori is the most clinically-
relevant ou tcome of H. pylori t reatment. Eradication treat­
ment should aim at an eradication rate of well over 8 0 % . 
It is now accepted that one should use a PPI-based triple 
therapy for seven days, using two antibiotics (clarithromy­
cin, amoxicil l in, tetracycline or metronidazole) [75 ,76] . A 
recent meta-analysis showed the superiority of combining 
two antibiotics, as opposed to one antibiotic alone, with 
acid-lowering therapy [77]. PPI (omeprazole) alone has 
been shown to reduce bacterial density in the antral muco­
sa, but does not eradicate H. pylori [78]. Pre-treatment with 
omeprazo le alone resulted in substantially lower eradica­
t ion rates ( 2 8 % ) [78]. 
Table 5 (consensus s tatement of the American College of 
Gastroenterology, 1996) gives a summary of the efficacy 
of different drug combinat ions and H. pylori cure rates 
[76]. 
Within the context of a randomised trial, success rates for 
eradicat ion therapy generally reflect efficacy. If good com­
pliance can be achieved, the effectiveness of the various 
H. pylori eradicat ion regimens was 8 4 % in an ongoing 
communi ty-based study [79]. There is now evidence that 
eradicat ing H P in pat ients who present with a bleeding ul­
cer reduces the risk of rebleeding [ 8 0 - 8 3 ] . 
The Maastr icht consensus report [75], representing current 
European concepts in the management of HP infection, 
stated that eradication treatment is strongly recommended 
in the following situations: infected peptic ulcer patients 
including those in remission or receiving long-term anti-se­
cretory therapy, patients with bleeding peptic ulcer, low-
grade M A L T lymphoma, gastritis with severe macro- or 
microscopic abnormal i t ies , and following resection of gas­
tric cancer. M A L T lymphomas often regress completely 
after eradication, rendering gastrectomy unnecessary [ 8 4 -
86] . 
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Table 5 Cure rates of various Helicobacter pylori eradication regi­
mens (Soil [76]) 
Drug combination (duration) HP cure rates ( 9 5 % CI) 
MOC (1 wk) 8 7 - 9 1 
AOC (1 wk) 8 6 - 9 1 
MOA (1 wk) 7 7 - 8 3 
BMT (1 wk) 8 6 - 9 0 
BMT (2 wk) 8 8 - 9 0 
BMT + 0 ( 1 wk) 9 4 - 9 8 
BMA (1 wk) 7 5 - 8 1 
BMA (2 wk) 8 0 - 8 6 
Legends: A: amoxicil l in, B: b ismuth, C: clar i thromycin, M: metronidazole, 
T: tetracycline, 0 : omeprazole 
Side-effects, usually mild, affect 1 0 % of pat ients receiving 
triple therapy including bismuth [87]. Omeprazole-based 
triple therapy was better tolerated than b ismuth-based ther­
apy in a randomised controlled trial [88]. 
Recurrence after Eradication Treatment 
Ulcer recurrence is significantly less c o m m o n a m o n g 
H. pylori-cured patients versus uncured patients ( 6 % vs . 
6 7 % for duodenal ulcer, 4 % vs. 5 9 % for gastric ulcer) 
[89]. The follow-up t ime in these studies ranged from six 
to 33 months . In a recently-published prospect ive long-
term follow-up study [90] in non-NSAIDs users with endo­
scopically confi rmed ulcer healing and eradicated H. py­
lori, no ulcer recurrence was detected over a period of up 
to 9.8 years. 
Confirmation of the success of Hel icobacter eradicat ion is 
generally considered necessary in patients with persist ing 
[80] or relapsing symptoms [87] after eradication therapy. 
Symptoms alone may not allow to dist inguish between ul­
cer recurrence and reflux esophagit is as a substantial 
( 1 0 % ) proportion of duodenal ulcer patients developed re­
flux esophagitis after H. pylori eradication [91]. Endoscopy 
therefore seems indicated in these cases. The annual re­
infection rate after successful eradication therapy is low 
(1 .2%) [92]. 
Impact of Endoscopy on Patient Outcome 
There is only limited direct evidence of endoscopic impact 
on outcome in patients with dyspepsia; that is, studies 
comparing the ou tcome of patients with dyspeptic symp­
toms who either did or did not undergo diagnost ic endos­
copy. Three studies merit discussion here. The first study 
[93] randomised dyspeptic patients to empirical H 2 -b locker 
therapy or endoscopy/upper GI series prior to prescript ion 
of H 2 -blockers . By the end of six months , H 2 -b locker use 
in both groups was similar (11 vs. 8 .7%) . Equal numbers 
of patients in each group were asymptomat ic (42.5 vs. 
39 .5%) . The second study [94] compared initial upper GI 
radiography to antacids and reassurance. After six months 
of fol low-up, there were no significant differences in 
symptoms , disability, satisfaction or quali ty of life scores 
between the two groups. The third study [95] compared 
prompt endoscopy with H 2 -b locker therapy. In contrast to 
the two other studies, this trial [95] showed better ou tcome 
(less work loss, less drug use) and lower costs in the group 
randomised to prompt endoscopy. Two-thirds of the pa­
tients initially randomised to empirical t rea tment were fi­
nally endoscoped at one year. In all three studies, Helico­
bacter pylori infection was not assessed. 
An alternative approach to establishing the efficacy of en­
doscopy in patients with dyspepsia is to examine popula­
tion trends. The first study [96] examined rates of peptic 
ulcer-related mortality, hospital isation, surgery, physician 
visits, work loss and disabili ty re t i rements in the US from 
1977 to 1986. All these factors decl ined over t ime. The 
t ime-scale trends described were attr ibuted to several fac­
tors, including the introduction of H 2 -b locke r therapy, re­
duction in smoking and possible changes due to the in­
creasing use of endoscopy. The second study [97] retro­
spectively reviewed the use of endoscopy compared to pep­
tic ulcer mortal i ty be tween 1979 and 1989. Al though the 
util isation of endoscopy rose from 21.7 to 25.6 procedures 
per t h o u s a n d the mortal i ty rate for pept ic ulcer disease in­
creased by 4 % in w o m e n whi le remaining stable in men. 
Death certification rates from peptic ulcer decl ined over 
the four decades in both sexes [98] . The main determinant 
of this is bel ieved to be the introduction of H 2 - recep to r an­
tagonists in the late 1970s, but other factors, such as ther­
apeutic endoscopy, may also have played a role. A popula­
t ion-based study [99] deal ing with diagnosis , t rea tment and 
prognosis of gastric cancer showed that endoscopy is pro­
gressively becoming the only viable diagnost ic tool. These 
changes in diagnost ic strategy were , however, associated 
with less remarkable t rends in t reatment and stage at diag­
nosis , thus failing to demonst ra te an important contribution 
by endoscopy to improving ou tcome of gastric cancer. In 
summary, populat ion studies and studies compar ing out­
come before and after introduction of endoscopy have gen­
erally not shown conclusively that the introduction of en­
doscopy substantially affected patient ou tcome. 
Clinical Practice: Management Strategies in Dyspepsia 
When developing appropria teness criteria for gastrointesti­
nal endoscopy, the st i l l -unanswered quest ion of how diag­
nosis and treatment of this condit ion should best be mana­
ged is crucial . Considerable confusion may exist in the lit­
erature as pr imary care physicians use the term "dyspep­
sia" in general to describe a complex of symptoms refer­
able to the upper digestive tract, whereas specialists 
(gastroenterologists) often refer to this te rm once endosco­
py is negative ( i .e . non-ulcer dyspepsia) . Increasing costs, 
efforts to contain costs, endoscopic workload and long 
wait ing lists do not allow endoscopy to be offered to every 
dyspeptic patient a l though there is evidence that symptoms 
show a poor predict ive value for endoscopic diagnoses [23, 
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31] , and that a " n o r m a l " result may substantially reduce 
work loss and medical care consumpt ion [24]. 
From a conceptual standpoint, endoscopy can be restricted 
to certain pat ients either based on the response to empirical 
therapy or based on criteria such as age, H P status, intake 
of N S A I D s or warning symptoms . Both approaches will be 
discussed briefly. 
Decis ion to Endoscope Based on the Response 
to Empirical Therapy 
In 1985, the Amer ican College of Physicians issued a prac­
tice guidel ine for dyspepsia [100], which was also adopted 
some years later by the Amer ican Society for Gastrointes­
tinal Endoscopy [101]. Al though not based on a clinical 
trial, this consensus s ta tement r ecommended empirical 
anti-secretory therapy in all patients with uncomplicated 
dyspepsia, reserving a diagnost ic upper GI endoscopy for 
those patients w h o did not respond to therapy or whose 
symptoms recurred on cessation of t reatment . This recom­
mendat ion was based on observat ions that a precise anato­
mical diagnosis did not impact on the choice of t reatment 
for most of the diseases associated with dyspeptic symp­
toms at that t ime. Fur thermore , it was hoped that empirical 
t reatment would improve case selection for organic d iagno­
ses at endoscopy. The role of empirical t reatment as a de­
cision tool for deciding on the use of endoscopy has been 
quest ioned. Bytzer [95] has shown that case selection of 
organic diagnoses is not rel iably enhanced by empirical 
t reatment as only 60 % of ulcer pat ients could be identified 
with this strategy. In addit ion, empirical therapy proved to 
be more expensive due to higher work loss and drug con­
sumption. Fur thermore , empirical t reatment pos tpones 
rather than e l iminates the need for endoscopy [102] as dys­
peptic symptoms recur and two-thirds of patients rando­
mised to empirical t rea tment were thus finally endoscoped 
after one year [95] . Empirical t reatment may also lead to 
an er roneous diagnosis of functional dyspepsia in patients 
with endoscopic lesions w h o have not experienced symp­
tom relief but have undergone comple te heal ing of the le­
sion (e .g . ulcer) because the relat ionship between symp­
toms and ulcer heal ing is not conclusive [102]. Empir ical 
therapy therefore proved to be a weak selection criterion 
for endoscopy. 
Decision to Endoscope Based on Specific Patient-Related 
Characterist ics 
Sobala [19] assessed a pol icy of screening dyspeptic pa­
tients before endoscopy using a strategy based on Hel ico­
bacter status and use of non-steroidal ant i - inf lammatory 
drugs. He used three criteria to identify patients expected 
to show a low yield from diagnost ic endoscopy: 1) age 
< 4 5 years; 2) negat ive H. pylori test, and 3) no history of 
N S A I D s use. The screening criteria were applied retrospec­
tively in 842 pat ients with known histological H. pylori sta­
tus, and prospectively to 293 pat ients referred for d iagnos­
tic endoscopy. Overal l , this screening strategy would have 
reduced endoscopy workload by 2 3 . 3 % and would have 
had a sensitivity rate for detection of peptic ulcer of 
9 7 . 4 % . N o peptic ulcer or mal ignant disease was missed 
in the patients studied prospectively, but six out of 192 
peptic ulcers in the histology ( i .e . , retrospective) group 
would have been missed. In another study [103], 52 sub­
jec ts aged 45 or less were screened by HP serology. All 
27 w h o were sero-negative had no ulcer disease while sev­
en out of 25 sero-posit ive patients had ulcer disease. 
Screening would have avoided 3 5 % of endoscopies in 
these patients while miss ing 1 3 % of patients with endo­
scopic findings (esophagit is and gastritis). In a further 
study [18], 183 dyspeptic patients aged < 4 5 were screened 
by a his tory-taking of sinister symptoms and regular use of 
N S A I D s , together with serological testing for H. pylori. 
Endoscopy was performed in 113 patients, of w h o m 90 
were sero-posit ive, 14 had sinister symptoms, and nine 
had used N S A I D s regularly. The remaining 70 patients 
w h o were H. pylori sero-negative had no sinister symptoms 
and had not taken N S A I D s , did not undergo endoscopy but 
received symptomat ic t reatment . Of these patients, only 
three were re-referred after screening for endoscopy. Thus. 
67 ( 3 7 % ) endoscopies were avoided. When the non-endos-
coped screening-negat ive patients were compared with the 
cohort of endoscoped screening-negative patients, there 
was no difference be tween the groups in terms of symptom 
severity. Medicat ion use was , however, significantly less in 
those pat ients who did not undergo endoscopy [18]. This 
study indicates that a screening based on H. pylori serolo­
gy, a history of sinister symptoms (e. g. weight loss, hemor­
rhage) or a his tory of N S A I D s use was beneficial in dys­
peptic pat ients . Thir ty-seven percent of endoscopies were 
avoided, and drug usage was reduced without disadvanta­
ging those patients not endoscoped. 
The above-ment ioned studies all took place in patients re­
ferred for endoscopy. Two randomized studies, published 
as abstracts in 1998, prospectively compared a "test and 
treat" strategy ( i .e . , H. pylori-posit ive patients with dyspep­
sia received eradication therapy without endoscopy) with 
p rompt endoscopy in pr imary care. In the first study [104] 
which included 500 pat ients , no difference between the two 
groups was found with respect to rate of symptom-free 
days, severity of symptoms or number of sick leave days 
after one year follow-up. However, the prompt endoscopy 
group resulted in higher patient satisfaction whereas the 
"test and treat" group was , not surprisingly, associated with 
a significant (63 % ) reduct ion in endoscopic work load. Pa­
tients with a larm symptoms were excluded from the study, 
and pat ients taking N S A I D s were automatical ly endos­
coped. The cost-effectiveness of a "test and treat" strategy, 
compared to prompt endoscopy, was confi rmed in another 
randomized control led trial [105]. However, none of these 
studies directly compared a "test and treat" strategy with a 
"test and scope" strategy (i. e., H. pylori-positive patients 
with dyspepsia are routinely endoscoped) in pr imary care. 
This might yield different results, in as much that the cost 
advantage of a "test and treat" strategy may be less evident 
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and the problem of overtreatment with eradication therapy 
(see below) would be avoided. 
The question of whether patients testing posit ive for Heli­
cobacter pylori should be endoscoped ("test and scope") or 
treated ("test and treat") cont inues to be hotly debated, 
with indirect evidence coming from several decis ion analy­
ses. The first decision analysis [106] in HP-posi t ive pa­
tients with dyspepsia concluded that initial anti-H. pylori 
therapy is the most cost-effective management strategy. 
Results were not substantially affected by varying the de­
gree of H. pylori eradication, by the side-effects of antibio­
tics, or the range of symptoms in curing H. pylori infec­
tion. Endoscopy-related costs would need to be reduced 
by 9 6 % before the two strategies become equally cost-ef­
fective. Another decision analysis [107] concluded that era­
dication treatment is less costly than H 2 -b locke r therapy in 
patients under 45 years of age with dyspepsia . The model 
in this study used endoscopy to identify appropriate pa­
tients to receive eradication t reatment (patients with ulcer 
disease). When the initial cost of identifying appropriate 
patients for eradication treatment is added to the analysis, 
the cost savings of eradication treatment take almost eight 
years to accrue. Similar results were obtained in a third de­
cision analysis [108]. A further decision analysis came to a 
different result. Direct medical charges in the first year 
after the onset of dyspepsia were compared be tween three 
strategies: prompt endoscopy, empirical therapy ( ^ - b l o c k ­
ers) or testing for H. pylori [109]. Medical charges were-
2162 US dollars for prompt endoscopy and 2122 US dol­
lars for empirical therapy. Initial non-invasive testing for 
H. pylori cost less than prompt endoscopy if H. pylori-posi­
tive patients with dyspepsia received ant imicrobial therapy 
without endoscopy (that is, "test and treat" strategy) but 
would have cost more if patients with H. pylori were routi­
nely endoscoped ("test and scope" strategy). The authors 
concluded that the choice of the opt imal management strat­
egy was a " toss-up". Only very modest savings may result 
from practice guidelines that r ecommend empirical ant i -HP 
therapy in the management of patients with dyspepsia . 
Table 6 "Test and scope" strategy 
Pros Cons 
Establishes clear diagnoses 
and allows biopsies 
Allows exclusion of neoplasia 
Reduces anxiety 
(patients' and physicians') 
Avoids over-treatment of 
patients w h o wou ld not need 
eradication therapy 
(e. g. esophagitis). 
Cost-effective if cost of 
endoscopy under 500 US 
dollars [110] 
Cost of endoscopy (variable 
according to country) 
Potential complications of 
upper GI endoscopy (rare) 
Inconvenience of endoscopy 
(unpleasantness, pain, t ime, 
etc.) 
Table 7 "Test and t reat" strategy 
Pros Cons 
Lowers the general HP 
prevalence and thus the 
future risk of gastric 
carcinoma and HP-related 
diseases 
Dramatic reduction of 
endoscopic work- load wi th 
consequent cost savings 
Allows management in 
primary care 
Over-treatment of patients 
w h o do not need eradication 
therapy (e.g. esophagitis/ 
reflux disease, non-ulcer 
dyspepsia) 
Potential deterioration of 
reflux symptoms 
Missing of significant 
endoscopic diagnoses 
(e.g. gastric ulcer, neoplasia, 
Barrett's esophagus) 
Development of resistance 
to antibiotics 
Side-effects of antibiotics 
Insufficient sensitivity and 
specificity of rapid HP 
serology kits 
At the present t ime, randomized studies directly compar ing 
the "test and scope" and the "test and t reat" strategies in 
primary care are needed to evaluate ou tcome and patient 
preferences. The value of each strategy will depend on the 
prevalence of H. pylori (low prevalence al lowing more sav­
ings than high prevalence in the "test and scope" strategy), 
the still unproved impact of H P eradication therapy on out­
come in documented non-ulcer dyspepsia, patient and doc­
tor preferences, and the cost of endoscopy (very variable 
according to the country) . As the cost of upper GI endos­
copy differs greatly between the United States (> 1000 U S 
dollars) and Europe, cost-effectiveness of upper GI endos­
copy must be judged differently. Thus , endoscopy may be 
cost competi t ive if its cost is 2 0 0 - 5 0 0 U S dollars [110] , 
which is the case in most European countries. The follow­
ing table briefly summarises the pros and cons of the "test 
and scope" (Table 6) and the "test and t reat" (Table 7) 
strategies: 
In conclusion, the quest ion of whether "test and scope" or 
"test and treat" should be the preferred managemen t strat­
egy remains open. Taking into account the uncertain effi­
cacy of eradicat ion t reatment in non-ulcer dyspepsia with 
the huge risk of "over t rea tment" in a test and treat strategy, 
the lower cost of endoscopy in Europe , current state of 
knowledge and all the pros and cons stated above, a "test 
and scope" strategy seems, at the present t ime, preferable. 
However, uncertainty will m a k e this quest ion one of the 
most prominent to be debated. 
Surveillance Endoscopy in Patients with Known 
Ulcer Disease 
It has become standard practice to follow gastric, but not 
duodenal ulcers endoscopical ly up to heal ing, because of 
concerns that gastric ulcers may represent early gastric ma­
lignancy. Diagnosis of gastric cancer in apparent ly benign 
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gastric ulcers has been reported in 1 to 6 % of pat ients wi th 
gastric ulcer [ 1 1 1 - 1 1 3 ] . Bytzer et al. evaluated the bene­
fits of routine endoscopic follow-up of gastric ulcer to de­
tect mal ignancy. They found that each curable gastric can­
cer was found at the expense of approximate ly 250 follow-
up endoscopies [114] . To our knowledge , there has been no 
randomized control led trial or prospect ive study compar ing 
ou tcome for pat ients with and without endoscopic follow-
up of gastric ulcer to heal ing. Two retrospective studies re­
viewed the clinical course in patients d iagnosed with gas­
tric ulcer. The first study [115] reviewed 148 gastric ulcers 
followed up by serial endoscopy over a 5-year period. One 
hundred and seven patients were followed to heal ing and 
41 cases did not heal. The average number of endoscopies 
per case was 2.7. O f 67 gastric cancers diagnosed during 
the same t ime period, 62 were suspected of being mal ig­
nant by their macroscopic appearance and only one cancer 
was missed after biopsy and/or brush cytology. The authors 
es t imate that favoring a policy of single endoscopy without 
follow-up when all signs indicate a benign ulcer would re­
sult in significant cost savings, as compared to the practice 
of routine follow-up endoscopy. Another study [111] 
looked at the impact of gastric ulcer surveil lance to detect 
gastric carc inoma after surgery. Patients wi th macroscopi -
cally and histologically benign gastric ulcer were asked to 
return after four weeks of therapy. Of 142 pat ients with an 
initial d iagnosis of benign gastric ulcer, 1.8% had mal ig­
nancy documented on repeat examinat ion. Fol low-up ex­
aminat ions did not, however, result in significant differen­
ces in 5-year survival rates. A large popula t ion-based long-
term cohort study [116] in hospital ised patients with gas­
tric or duodenal ulcers found that the risk of gastric cancer 
was almost twice the expected rate in patients with gastric 
ulcers, whereas the risk was less in patients with duodenal 
ulcers. The authors conclude that gastric ulcer disease and 
gastric cancer have etiological factors in c o m m o n . 
Dyspepsia in Patients Taking NSAIDs 
Prevalence of NSAID- Induced Gas t ro-Duodenal Disease 
The use of N S A I D s in the general populat ion is extremely 
frequent. In a popula t ion-based study in the U S A , age- and 
gender-adjusted annual prevalence rates for aspirin and 
non-aspir in N S A I D s use in the elderly were 6 0 % and 
2 6 % respectively [117]. Fifteen percent of these patients 
presented wi th dyspepsia , 1 3 % with hear tburn. N S A I D s 
are the second most c o m m o n cause of peptic ulcer and 
are now bel ieved to be responsible for the majority of 
those ulcers not associated wi th H. pylori infection [118]. 
In a meta-analys is of 16 studies from 1975 to 1990, exam­
ining the associat ion be tween N S A I D use and adverse gas­
trointestinal events, N S A I D users were calculated to be at a 
threefold greater risk of deve lopment of serious adverse 
events (GI bleeding, surgery or death) than non-users 
[119]. The risk appeared to be greatest in the first few 
months of t reatment , age > 6 5 , in the presence of concom­
itant steroid use and where there was a previous history of 
GI events [119] . In a case-control study [118] , the relative 
risk for development of peptic ulcer disease among current 
N S A I D users was 4 . 1 , with the greatest risk in the first 
month of use. N S A I D use is associated with a higher rate 
of dyspepsia [117]. However, symptoms are not strong pre­
dictors of the presence of endoscopic damage [120]. More 
recent N S A I D types have been claimed to have less dam­
aging effects on the gastro-duodenal mucosa, primarily by 
inhibit ing more selectively cyclooxygenase-2, and thus in­
creasing tolerabili ty [121 ,122] . Nabumetone thus seems to 
have significantly lower ulcerogenic potential than naprox­
en [123 ,124] , but probably also less clinical efficacy [124], 
N S A I D use is also associated with non-specif ic ulceration 
of the small intestinal mucosa ( 8 . 4 % of the patients) that 
can lead to l ife-threatening complicat ions [125]. 
NSAID- Induced Ulcer Disease and Helicobacter pylori 
In N S A I D s users , there is no difference in the frequency of 
dyspept ic symptoms between patients with and without HP 
infection, suggest ing that N S A I D s do not increase suscep­
tibility to Helicobacter infection [126 ,127] . A randomized 
study recently showed that eradication of Helicobacter py­
lori before starting N S A I D s therapy reduces the occurrence 
of NSAID- induced peptic ulcers [128]. In this study, H. py­
lori seems to have a pathogenic role in NSAID-induced ul­
cer disease. In contrast , three randomized trials published 
as abstracts in 1998 failed to show a beneficial impact of 
HP eradicat ion on NSAID- induced ulcers. Thus eradication 
t reatment did not accelerate the heal ing of already estab­
lished ulcers [129] nor prevent the development of ulcers 
in long-term N S A I D users . [130]. A third trial even 
showed that eradicat ion treatment was associated with re­
duced ulcer heal ing [131] . In conclusion, eradication of 
H P in chronic N S A I D users is probably not justified. 
Prophylaxis of NSAID- Induced Ulcers 
A large meta-analys is on the prevention of NSAID-induced 
mucosal injury in 4,325 pat ients [132] concluded that mi­
soprostol , but not H 2 -b lockers , reduced the risk of gastric 
ulcers. It was also found that both misoprostol and H 2 -
blockers prevented duodenal ulcer in long-term NSAIDs-
users . These findings were conf i rmed in other randomised 
control led trials [ 1 3 3 - 1 3 5 ] . Misoprostol was also shown to 
significantly reduce serious NSAID- induced upper gastro­
intestinal compl ica t ions such as perforation, gastric outlet 
obstruction and bleeding. These results were obtained in 
large, well-conducted, randomised trials in 8,843 patients 
wi th chronic rheumatoid arthritis [134]. However, miso­
prostol is often associated with side-effects such as diar­
rhea and abdominal c ramps [136]. The prophylactic effect 
of omeprazo le in N S A I D s users was recently assessed in a 
placebo-control led, randomised study [136]. During a 3-
mon th study period, 4 . 7 % of omeprazole- treated patients 
developed duodenal or gastric ulcers, compared with 
1 6 . 7 % of placebo-treated patients. In addition, the devel­
opment of dyspept ic symptoms was also significantly re­
duced with omeprazol , compared to placebo. 
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In a double-blind randomized study publ ished in 1998 
[137], omeprazole healed and prevented ulcers more effec­
tively than did ranit idine in N S A I D s users. Another dou­
ble-blind randomized trial compar ing omeprazo le 20 mg, 
40 mg or misoprostol 800 mg daily found that the overall 
healing rates of ulcers and symptoms were similar for the 
three t reatment regimens. However, omeprazole was better 
tolerated and associated with a lower rate of relapse during 
maintenance treatment than misoprostol [138]. 
Impact of Endoscopy in N S A I D s Users 
There are to our knowledge no studies compar ing ou tcome 
of patients with uncompl ica ted NSAID- induced peptic dis­
ease with and without endoscopy. 
Stress Ulcer 
Although endoscopic studies have demonst ra ted gross mu­
cosal injury within hours of a stressful event in nearly 
1 0 0 % of patients examined, most stress ulcers heal when 
normal gastric defence mechan i sms are restored. In a ran­
d o m i s e d controlled trial [139] , 8 0 % of patients requir ing 
aortic surgery developed stress ulcers post-operatively. A 
rigorously-conducted meta-analysis publ ished recently 
[140], and including 63 randomised trials in 7,218 patients , 
addressed ulcer prophylaxis in critically-ill adult patients. 
Sucralfate was associated with a lower morbidi ty rate com­
pared with antacids and a trend towards lower mortal i ty 
when compared with H 2 - recep tor antagonists . However, 
none of the three t reatments studied (sucralfate, ^ - r e c e p ­
tor antagonists , NSAIDs) revealed a significant effect on 
mortality rate. Stress-ulcer bleeding is rare ( 1 - 1 . 5 % ) 
[141 ,142] . Sucralfate significantly decreased overt bleed­
ing in comparison with both placebo and N S A I D s . For 
clinically-important bleeding, H 2 - recep tor antagonists re­
mained superior to placebo. 
The role of PPI in stress ulcer prophylaxis has been studied 
in a recent randomized trial. Sixty-seven high-risk patients 
were randomized to receive either ranit idine 1 5 0 m g or 
omeprazole 40 mg per day [143]. Eleven patients in the ra­
nitidine and two patients in the omeprazole group devel­
oped clinically important bleeding ( p < 0 . 0 5 ) . Despite its 
potent acid inhibition, nosocomial pneumonia was seen in 
one patient only under omeprazole , compared to 5 patients 
receiving ranitidine. Further studies are needed to deter­
mine the role of PPI in stress ulcer prophylaxis [144]. 
Only a small proport ion of patients present ing with com­
plications such as gastrointestinal hemor rhage or perfora­
tion, require medical and/or surgical intervention [145]. 
The role of endoscopy in bleeding stress ulcers is discussed 
in a separate publication (upper gastrointestinal bleeding 
and other alarm symptoms) [146]. 
Complicated Peptic Ulcer Disease 
Hemorrhage as a compl ica t ion of ulcer disease has been 
dealt with in a separate publ icat ion [146]. The ep idemiolo­
gy of pept ic ulcer perforation has evolved over the past 50 
years: incidence has d ec r ea s ed except in women over 65 
years of age, and there has been an increase in m e a n age 
at t ime of perforation and a decrease of the m a l e : f e m a l e 
ratio [147]. The short- term mortal i ty of pept ic ulcer dis­
ease has fallen from 1952 to 1990 [148]. Uncer ta inty re­
mains about the role of Hel icobacter pylori in the pa tho­
genesis of ulcer perforation since 5 0 % of pat ients with 
perforation seem to be HP-negat ive [147] . The single most 
important risk factor associated with both ulcer perforation 
and ulcer bleeding is the increasing use of N S A I D s [147]. 
The localisation of perforation has also changed over t ime, 
wi th perforation now being more frequently encountered in 
the pyloric and prepyloric area than in the d u o d e n u m [149]. 
Gastric Cancer 
Prevalence, Incidence and Risk Factors of Gastric Cancer 
The prevalence of gastric cancer in dyspept ic patients in 
Europe is in the order of 1 - 2 % . In three recent prospec­
tive studies [ 1 7 , 2 0 , 2 1 ] , two gastric cancers were found in 
2,598 dyspept ic patients under 40 years of age (0.8 % o ) , vs. 
88 cases in 4,843 pat ients over 40 to 45 years ( 1 . 8 % ) , 
showing a striking higher-age p redominance wi th gastric 
cancer being very rare in young dyspept ic pat ients . 
Fifty years ago, s tomach cancer was the leading cause of 
death from cancer in males in the U S A . Since then, morta l ­
ity and incidence have decreased virtually everywhere . 
There is a band of high- and above-average incidence from 
Central Italy to the Swiss border, cont inuing through Ba­
varia up to the Danish border, whi le the south of Italy, 
Great Britain and most of France are either average or be­
low-average [150 ,151] . These t rends are bel ieved to be due 
to changes in food preparat ion and storage, and differences 
in consumpt ion of fruit and vegetables . Classical risk con­
dit ions for gastric cancer are the following [152]: chronic 
atrophic gastritis and intestinal metaplasia , pernic ious ane­
mia, partial gast rectomy for benign disease, Hel icobacter 
pylori infection, Mene t r ie r ' s Disease, gastric adenomatous 
polyps. Genet ic and environmental factors include a family 
history of gastric cancer, low consumpt ion of fruit and 
vegetables , consumpt ion of s a l t ed smoked foods, cigarette 
smoking, low social and economic status, and b lood type 
A. 
Hel icobacter pylori was declared a Class I carcinogen in 
June 1994 (World Health Organisat ion) . Available evidence 
on the relat ionship between Hel icobacter pylori and gastric 
cancer was assessed in a 1996 consensus s tatement [153]. 
H P is the major cause of multifocal atrophic gastritis and is 
also believed to lead to the development of intestinal meta­
plasia [98], whi le chronic gastritis is clearly not associated 
with any increased risk of cancer [153]. The Eurogast 
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Study Group [41] , a prospect ive epidemiological study in 
over 3,000 subjects of 14 populat ions in Europe , U S A and 
Japan, found a six-fold increased risk of gastric cancer in 
populat ions with 100 % H P infection compared with popu­
lations without infection. The hypothesis that H P infection 
is a risk factor for gastric cancer is further endorsed by 
three large case-control led studies [ 1 5 4 - 1 5 6 ] . Most per­
sons infected with H P will , however, never develop a gas­
tric carc inoma and other factors that increase the risk of 
carc inoma a m o n g persons infected with H P therefore need 
to be identified [156]. Early-life infection by Hel icobacter 
pylori increases the risk of developing both gastric cancer 
and gastric ulcers [157]. 
Hel icobacter pylori infection is invariably associated with 
the presence of lymphoid follicles which are precursors of 
M A L T lymphomas [153]. There is evidence that the suc­
cessful cure of Hel icobacter pylori infection results in the 
regression, and perhaps even the cure, of M A L T lymphoma 
in 5 0 - 7 5 % of patients [84]. 
Symptoms of Gastric Cancer 
Al though gastric cancer is a mat ter of concern for clini­
cians evaluating patients with dyspepsia , mos t pat ients with 
gastric cancer do not develop symptoms or signs until the 
disease is no longer curable. Superficial and surgically cur­
able gastric carc inoma typically produce no symptoms 
[152]. In a prospect ive series of 720 pat ients with gastric 
carc inoma, only 8 % were eligible for curative resection 
[158]. In a large review performed by the Amer ican Col­
lege of Surgeons [152] , weight loss ( 6 2 % ) and abdominal 
pain ( 5 2 % ) were the most frequent symptoms at the t ime 
of initial d iagnosis . Abou t 1 0 % of all gastric cancer pa­
tients present with hematemes i s or melena , and patients 
present ing with bleeding rarely have early cancers [159]. 
Histological Issues in Gastric Cancer 
Differences in diagnost ic criteria for gastric carc inoma be­
tween Japanese and Western pathologists may contr ibute to 
the relatively high incidence and good prognosis of gastric 
cancer in Japan. Thus , in Japan, gastric carc inoma is diag­
nosed on nuclear and structural criteria even w h e n invasion 
is absent according to the Western viewpoint [160]. In a 
prospect ive, mul t i -center study, it was found that gastric 
cancer was associated wi th 3 6 % of modera te and with 
8 0 % of severe gastric epithelial dysplasia; the follow-up 
of patients with dysplasia considerably enhances the chan­
ces of d iagnosing gastric cancer in its early stages [161]. In 
these patients , a repeat endoscopy every three months is re­
c o m m e n d e d in presence of modera te dysplasia with im­
media te control endoscopy and mult iple biopsies in the 
presence of severe dysplasia. 
Impact of Endoscopy on Detection Rate 
There have been important changes in the diagnostic strat­
egy for gastric cancer, endoscopy being now the most fre­
quently-used diagnostic tool [99]. The proportion of resec­
tions for cure increased from 38 to 5 0 % , as did the propor­
tion of cases confined to the gastric wall ( 6 - 12%) . The in­
vestigation of dyspeptic patients over 40 years of age after 
their first consultat ion with the general practit ioner could 
increase the proport ion of early gastric cancers detected to 
2 6 % and the proport ion of operable cases to 6 3 % [162]. 
The most obvious trends in the management of gastric can­
cer c o m e from the reduct ion of operative mortality rate. 
Endoscopic surveil lance in post-gastrectomy patients, aim­
ing at detect ing early gastr ic-s tump cancer, does not seem 
to reduce mortal i ty [163] , and the risk of developing gas­
tric cancer in these pat ients does not seem to be enhanced 
as compared to the general populat ion [164]. Endoscopic 
ul trasound has been shown to better assess T and N cate­
gories pre-operat ively than computed tomography or inter-
operative surgical assessment [ 1 6 5 - 1 6 7 ] . 
2. Panel Results 
Consider ing the above review of relevant literature, the pa­
nel evaluated 192 specific theoretical patient scenarios 
related to the use of gastrointestinal endoscopy in patients 
with dyspepsia . 
Definition of Terms 
All te rms and definit ions were reviewed and approved by 
the panelists before proceeding to ratings of clinical indica­
t ions; they are listed in Table 8. 
Clinical Variables 
The clinical variables used to describe the list of indica­
t ions related to dyspepsia are shown in Table 9. The main 
variable used to structure the list of indications for dyspep­
sia was the parameter of previous investigations, resulting 
in four main sub-categories. 
General Panel Results 
Dyspeps ia was assessed by 192 clinical scenarios within 4 
sub-categories: no previous investigation done (48 items), 
previous or upper GI (UGI) series upper GI endoscopy 
(UGE) normal (48 i tems), U G E or UGI series done and 
showing duodenal or prepyloric ulcer, duodenit is or erosive 
gastritis (48 i tems), and U G E or UGI series showing gas­
tric ulcer (48 items). Of the 192 scenarios, the panel rated 
113 ( 5 9 % ) as inappropriate , 31 ( 1 6 % ) as uncertain and 48 
( 2 5 % ) as appropriate . The rate of overall agreement be­
tween panelists was high ( 7 2 % of the scenarios). Although 
a dist inction was initially m a d e between first/second and 
recurrent episodes, the panelists did not wish to maintain 
this distinction, arguing that their clinical judgment would 
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Table 8 Definition of terms 
Dyspepsia 
is defined as pain or discomfort in the upper abdomen, including 
nausea, vomit ing, early satiety, epigastric fullness, but not heart­
burn or dysphagia.(Isolated heartburn or regurgitation are dealt 
wi th in the article on reflux disease [10], 
Uncomplicated dyspepsia 
Dyspepsia wi thout alarm symptoms. (Hematemesis, melena, 
esophageal dysphagia, unexplained weight loss, iron-deficiency 
anemia are dealt w i th in the article on alarm symptoms [146]. 
Episode of dyspepsia 
Minimum duration to be considered as one episode: 4 weeks. 
Time interval for the definit ion of the onset of a new episode: 
1 month free of symptoms wi thout treatment. 
Eradication treatment for Helicobacter pylori infection 
Treatment regimen composed of t w o antibiotics and an PPI/H2 
blocker wi th an eradication rate supposed to exceed 9 0 % . 
Helicobacter test 
According to the situation, either a non-endoscopic test 
(serology, C 1 3 breath-test), or an endoscopic test (urease test, 
histology, culture). 
Empirical acid-lowering treatment 
In order to serve as a decisional tool for the panel, the minimum 
duration of treatment is > 1 week of continuous intake. The type 
of treatment is either standard doses of an PPI (e.g. omeprazole 
20 mg/d, lansoprazole 30 mg/d, or pantoprazole 40 mg/d) or 
H 2-blockers (e.g. ranitidine 300mg/d) or continuous high-dose 
antacid treatment (e. g. 4 x 5 ml/d aluminium hydroxide, sucralfate 
2 x 2 g/d etc). 
NSAIDs intake 
Continuous intake of NSAIDs for > 3 days, or intermittent intake 
of NSAIDs at onset of symptoms at least every 2 days for at least 
1 week 
Previous investigations 
A previous investigation by either an UGI endoscopy or UGI series 
performed within 2 years of the present episode of dyspepsia. 
be similar in each case. Appropr ia teness is def ined in a se­
parate publ icat ion in this issue of the Journal [1]. 
Specific Clinical Panel Results 
Descript ion of Appropr ia teness 
The main results related to appropr ia teness are worded as 
an overall s ta tement (Table 10) encompass ing several clini­
cal scenarios (clustering). In some cases , the same scenario 
may apply to more than one statement . One hundred and 
sixty-seven of the 192 indicat ions ( 9 4 % ) could be charac­
terized by the eight overall s ta tements given below. Detai led 
appropriateness and necessi ty criteria encompass ing all 192 
indicat ions are available in a computer ized form accessible 
via Internet (ht tp: / /www.epage.ch) . 
In HP-posi t ive pat ients wi th persis t ing symptoms and not 
having received eradicat ion t reatment , we assessed whether 
panelists would favor a " tes t -and-scope" strategy ( i .e . , en­
doscope dyspept ic pat ients testing posi t ive for H. pylori) or 
a " test-and-treat" strategy (i. e., treat dyspept ic pat ients em­
pirically if test ing posit ive). Sixteen scenarios pertain to 
this situation. In pat ients > 4 5 years of age, the " test-and-
s c o p e " strategy was favored unless previous investigations 
showed duodenal or prepyloric ulcer or duodenit is . In the 
presence of a previous history of gastric ulcer, the "test-
and- scope" strategy was always preferred. The "test-and-
treat s t ra tegy" was preferred if previous investigations had 
shown duodenal or prepyloric ulcer or duodeni t is , or in pa­
tients < 4 5 years of age in w h o m previous U G E or U G I 
series were normal . 
Table 9 Clinical variables used in individuals presenting w i th dyspepsia (192 indications) 
Variables Number of categories Categories 
Age 2 - > 4 5 years old 
- < 4 5 years old 
NSAIDs 2 - no 
- yes 
Helicobacter pylori 3 - no HP test 
- HP test negative 
- HP test positive 
Previous investigations of similar symptoms 4 - no previous investigation or previous investigation 
w i th results unknown 
- UGI endoscopy or UGI series w i th normal results 
- UGI endoscopy or UGI series showing duodenal 
ulcer, prepyloric ulcer, duodenitis or erosive gas­
tritis 
- UGI endoscopy or UGI series showing gastric ulcer 
Empirical acid-lowering treatment 2 - no treatment or inadequate treatment 
(in HP-negative patients) or HP eradication - adequate treatment given 
treatment (in HP-positive patients) 
Response to empirical acid-lowering or HP 2 - symptoms not resolved 
eradication treatment, respectively - symptoms resolved 
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Table 10 Description of appropriateness of indications for upper 
gastrointestinal endoscopy in individuals wi th dyspepsia 
Clinical Situation 
In individuals wi th uncomplicated dyspeptic symptoms that 
resolved wi th or w i thou t treatment, indication for gastrointestinal 
endoscopy is generally inappropriate w i th the exception of some 
scenarios related to patients > 45 years old wi th previous gastric 
ulcer (uncertain) 
In individuals w i th persistent dyspepsia, and wi th a previous history 
of gastric ulcer, indication for gastrointestinal endoscopy is 
appropriate 
In individuals aged 45 and over wi th persistent dyspepsia, and 
wi thout any previous investigations or w i th unknown results of 
previous investigations, indication for gastrointestinal endoscopy 
is appropriate 
In individuals aged 45 and over wi th persistent dyspepsia, and 
normal results of previous investigations of similar symptoms, 
indication for gastrointestinal endoscopy is generally uncertain 
unless symptoms persist after HP eradication has been given in 
a HP-positive patient (appropriate) 
In individuals aged 45 and over wi th persistent dyspepsia, and 
previous investigations showing duodenal ulcer, prepyloric ulcer 
or duodenitis, indication for gastrointestinal endoscopy is 
generally uncertain 
unless empiric acid lowering treatment has been given and HP test 
is negative (appropriate) 
unless symptoms persist after HP eradication has been given in a 
HP-positive patient (appropriate) 
In individuals aged less than 45 w i th persistent dyspepsia, and 
wi thout any previous investigations or w i th unknown results of 
previous investigations, indication for gastrointestinal endoscopy 
is generally uncertain 
unless HP test is unknown and no empirical acid-lowering treat­
ment has been given (inappropriate) 
unless symptoms persist after HP eradication has been given in a 
HP-positive patient (appropriate) 
In individuals aged less than 45 w i th persistent dyspepsia, and 
normal results of previous investigations of similar symptoms, 
indication for gastrointestinal endoscopy is inappropriate 
unless symptoms persist after HP eradication has been given in a 
HP-positive patient (uncertain) 
In individuals aged less than 45 w i th persistent dyspepsia, and 
previous investigations showing duodenal ulcer, prepyloric ulcer 
or duodenitis, indication for gastrointestinal endoscopy is 
inappropriate 
unless empirical acid lowering treatment has been given and HP 
status is negative or unknown (uncertain) 
unless symptoms persist after HP eradication has been given in a 
HP-positive patient (appropriate) 
Descr ipt ion of Necess i ty 
Twelve out of 192 scenarios ( 6 . 3 % ) were j u d g e d necessary. 
All necessary indicat ions (Table 11) in uncompl ica ted dys­
pepsia per ta ined to pat ients > 45 years of age. Necessi ty is 
defined in a joint publ icat ion in this issue of the Journal [1]. 
3. Conclusions 
The current literature under l ines the frequent occurrence of 
dyspepsia in clinical pract ice and the wide variat ions in 
diagnosis and treatment . The advent of Hel icobacter pylori 
Table 11 Description of necessity of indications for upper gastro­
intestinal endoscopy in individuals wi th dyspepsia 
Clinical situation 
In individuals > 4 5 years of age testing positive for HP, wi th 
persisting symptoms despite eradication treatment, indication 
for gastrointestinal endoscopy is necessary 
In individuals > 4 5 years of age, never investigated, HP-negative 
and no NSAIDs intake, wi th persisting symptoms despite acid-
lowering treatment, indication for gastrointestinal endoscopy is 
necessary 
In individuals > 4 5 years of age w i th a previous history of gastric 
ulcer, no HP testing or HP test negative, w i th persisting symptoms 
despite acid-lowering treatment, indication for gastrointestinal 
endoscopy is necessary 
as well as the need for cost conta inment in almost all de­
veloped countries have had a profound impact on diagnos­
tic and therapeutic strategies in dyspepsia which are cur­
rently hotly debated and widely assessed. The literature 
suggests that U G E should be used in patients with a rea­
sonably high probabil i ty of a clinically relevant diagnosis 
such as ulcer disease or cancer. 
One third of EPAGE criteria related to dyspepsia. EPAGE 
criteria j udged performance of U G E often inappropriate 
( 5 9 % ) in uncompl ica ted dyspepsia. Very few situations 
( 6 % ) were judged necessary. Six clinical and circumstan­
tial parameters permit ted detailed assessment of all possi­
ble scenarios: patient age, N S A I D s intake, Helicobacter 
status, results of previous U G E or UGI series, whether or 
not empirical antisecretory treatment was given and the 
clinical response to this t reatment . Although highly de­
tailed and specific, 9 4 % of the scenarios could be encom­
passed in simple, descriptive s tatements applicable to clin­
ical practice. However, the full potential and utility of these 
criteria will become apparent on the computer ised version 
accessible via Internet (ht tp: / /www.epage.ch) that will per­
mit easy applicat ion of all scenarios even in the most com­
plex situations. 
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